Issues important for rational COMT inhibition

Neurology

Volumn 55, Issue 11 SUPPL. 4, 2000, Pages

  Dingemanse, J ^a   Waters, ^a   Schapira, ^a   Nutt, ^a   Obeso, ^a   Reichmann, ^a   Olanow, ^a   Gordin, ^a   Stocchi, ^a   Rascol, ^a   Hauser, ^a   L eWitt, ^a   Jenner, ^a   Hubble, ^a  

^a Jacor Research   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; BENSERAZIDE; CARBIDOPA; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; ENTACAPONE; LEVODOPA; TOLCAPONE;

AREA UNDER THE CURVE; ARTICLE; DOSE RESPONSE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; HALLUCINATION; HUMAN; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL;

BENZOPHENONES; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; HUMANS; LEVODOPA; NITROPHENOLS; PARKINSON DISEASE;

EID: 0034642349     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Treatment of Parkinson's disease
2. New and emerging strategies for improving levodopa treatment
3. Catechol-O-methyltransferase: Pharmacological aspects and physiological role
4. Immunohistochemical study of catechol-O-methyltransferase in the human mesostriatal system
5. Decarboxylase inhibitors
6. Dopamine is a monoamine oxidase B substrate in man
7. The interaction of transport mechanisms and intracellular enzymes in metabolizing systems
8. Catechol-O-methyltransferase inhibitors: Clinical potential in the treatment of Parkinson's disease
9. Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects
10. Tolcapone and neurotoxicity in Parkinson's disease
11. Microdialysis studies on the action of tolcapone on pharmacologically-elevated extracellular dopamine levels in conscious rats
12. Inhibition of catechol-O-methyltransferase (COMT) in the brain does not affect the action of dopamine and levodopa: An in vitro electrophysiological evidence from rat mesencephalic dopamine neurons
13. The effect of tolcapone on central and peripheral COMT activity in normal humans and Parkinson's disease: A PET study
14. A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients
15. Clinical pharmacokinetics of anti-parkinsonian drugs
16. Multiple-dose clinical pharmacology of the catechol-O-methyltransferase inhibitor tolcapone in elderly subjects
17. The effect of catechol-O-methyltransferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers
18. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa
19. Catechol-O-methyltransferase (COMT): Biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors
20. COMT inhibition by high-dose entacapone does not affect haemodynamics but changes catecholamine metabolism in healthy volunteers at rest and during exercise
21. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, and Sinemet on intestinal electrolyte and fluid transport in conscious dogs
22. Tolcapone and fulminant hepatitis
23. The rise and fall of tolcapone
24. Tolcapone (Tasmar) and hepatotoxicity
25. Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production
26. The effect of tolcapone on the pharmacokinetics of benserazide
27. Improved therapy of Parkinson's disease with tolcapone, a central and peripheral COMT inhibitor with an S-adenosyl-L-methionine-sparing effect